GoffinetLab
@goffinetlab.bsky.social
Chair in Virology @LSTM, UK | HIV-1, alphaviruses, SARS-CoV-2, MPXV | AIVE - Antiviral Immunity and Viral Evasion | Alumna of Charité - Universitätsmedizin Berlin, Germany
https://www.lstmed.ac.uk/about/people/professor-christine-goffinet
https://www.lstmed.ac.uk/about/people/professor-christine-goffinet
3/ in "shock-and-kill" approaches, as we found (link to studies below). Indeed, the authors don't seem to generate evidence for detectable reduction of the reservoir size, and (temporal) virus control seems to be achieved predominantly by T-cell responses. #HIVCure is not around the corner!
December 23, 2025 at 7:10 PM
3/ in "shock-and-kill" approaches, as we found (link to studies below). Indeed, the authors don't seem to generate evidence for detectable reduction of the reservoir size, and (temporal) virus control seems to be achieved predominantly by T-cell responses. #HIVCure is not around the corner!
2/ special profile from start on which may potentially have facilitated things). I really do wonder if the chosen LRA, the TLR9 agonist lefitolimod, modulates cell surface Env presentation (important for ADCC), and/or apoptosis. Many (but not all!) LRAs do, and paradoxically impede "kill"
December 23, 2025 at 7:10 PM
2/ special profile from start on which may potentially have facilitated things). I really do wonder if the chosen LRA, the TLR9 agonist lefitolimod, modulates cell surface Env presentation (important for ADCC), and/or apoptosis. Many (but not all!) LRAs do, and paradoxically impede "kill"
1/ I agree that (even functional) #HIVCure will probably need a multi-component and staged strategy, and is not close. This multi-pronged approach shows, 18 months post ATI, a delay of viral rebound in 6/9 participants, and remission in 1/9 participants (though the latter seems to display a
December 23, 2025 at 7:10 PM
1/ I agree that (even functional) #HIVCure will probably need a multi-component and staged strategy, and is not close. This multi-pronged approach shows, 18 months post ATI, a delay of viral rebound in 6/9 participants, and remission in 1/9 participants (though the latter seems to display a
Definitely exciting and even more puzzling. Note that the patient himself was heterozygous for CCR5delta32. So either there is a dosage effect of truncated CCR5, and/or (more provocative) the CCR5 genotype is less relevant than we all anticipated and the allo-SCT per se does large part of the trick?
December 23, 2025 at 6:09 PM
Definitely exciting and even more puzzling. Note that the patient himself was heterozygous for CCR5delta32. So either there is a dosage effect of truncated CCR5, and/or (more provocative) the CCR5 genotype is less relevant than we all anticipated and the allo-SCT per se does large part of the trick?
Of course, costs for Skilled Worker VISA application and NHS surcharges will be covered by LSTM.
January 29, 2025 at 10:18 PM
Of course, costs for Skilled Worker VISA application and NHS surcharges will be covered by LSTM.